AML-ALL

Professor Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematology at University Hospitals Birmingham.. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He is a past President of the British Society of Haematology. Professor Craddock’s main research interests include the development of novel drug and transplant therapies in acute myeloid leukemia. 

He pioneered the development of the UK Haemato-oncology Trials Acceleration Programme and the UK stem cell transplant trials network, IMPACT. He has published more than 250 papers in peer reviewed journals. Professor Craddock was awarded the CBE for services to medicine and medical research in the 2016 New Year’s Honours list and elected a Fellow of the Academy of Medical Sciences in 2020.

Hematologist, she’s working at the Institute of Hematology “L. and A. Seragnoli” in Bologna, Italy, and she’s Adjunt Professor of Hematology at Bologna University.
She’s involved in AML, ALL, Systemic Mastocytosis, HES and BPDCN patients’ care and clinical research programs. She’s leading as PI, more than 60 phase 1-2-3 clinical trials in the field, and she’s author of more than 120 peer-reviewed publications. Since 2005, year of her graduation, she has been speaker at several national and international congresses.

She’s member of the main hematology and cancer societies (SIE, SIES, EHA, ASH, AACR, SOHO, SOHO Italy, ESMO), Faculty Member of Hematological Malignancies Board (ESMO) since 2021, EHA Master Class Mentor since 2021 and Member of AML SWG (EHA) since 2023. She has served as reviewer for several hematology journals.

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. 

This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine).

The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.

Dr Naval Daver is an associate professor and director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease, and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr Daver has published over 300 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms